In a 16‑year‑old adolescent on a psychostimulant (e.g., methylphenidate or amphetamine) with blood pressure at the 97th percentile for age, sex, and height, can the stimulant be continued?

Can Psychostimulants Continue in a 16-Year-Old with Blood Pressure at the 97th Percentile?

Yes, the psychostimulant can be continued with intensified blood pressure monitoring and initiation of antihypertensive therapy if needed, because blood pressure at the 97th percentile represents "elevated BP" rather than hypertension in this age group, and current guidelines do not mandate stimulant discontinuation at this threshold. 1

Blood Pressure Classification in Adolescents ≥13 Years

• The 2017 AAP guideline defines elevated BP (not hypertension) as BP readings ≥90th percentile and <95th percentile for age, sex, and height, or 120–129/<80 mmHg in adolescents ≥13 years. 1

• Hypertension is defined as BP ≥95th percentile (approximately ≥130/80 mmHg in adolescents ≥13 years), which this patient has not yet reached. 1

• The 97th percentile falls into the "elevated BP" category—a zone of heightened risk but not yet meeting criteria for stage 1 hypertension. 1

Guideline Recommendations for Stimulant Continuation

• The American College of Cardiology/American Heart Association recommends that stimulants be used with caution in patients with pre-existing hypertension but does not mandate discontinuation for elevated BP below the hypertensive threshold. 2

• Discontinuation or dose reduction is explicitly recommended when BP rises to ≥130/80 mmHg (stage 1 hypertension), not at the 97th percentile. 2

• The FDA label for methylphenidate requires monitoring BP and heart rate but does not list elevated BP (below hypertensive range) as a contraindication to continued use. 3

Required Monitoring and Management Steps

Confirm the Blood Pressure Elevation

• Obtain repeat BP measurements using home blood pressure monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM) to exclude white-coat hypertension before making treatment decisions. 1, 2

• Diagnosis of hypertension requires demonstration of elevated or hypertensive-level BP at three separate encounters unless the patient is symptomatic. 1

Intensify Blood Pressure Monitoring

• Check BP at every dose adjustment of the stimulant medication and at least quarterly during stable dosing. 2

• The American Academy of Child and Adolescent Psychiatry recommends monitoring BP and pulse at each dose adjustment. 2

Consider Antihypertensive Therapy if BP Progresses

• If repeat measurements confirm progression to stage 1 hypertension (≥130/80 mmHg), initiate antihypertensive therapy with first-line agents (ACE inhibitor, ARB, calcium channel blocker, or thiazide diuretic) while continuing the stimulant. 2

• The target BP should be <130/80 mmHg before considering any change to ADHD medication. 2

Optimize Stimulant Formulation

• Long-acting stimulant formulations are preferred over short-acting preparations because they provide smoother cardiovascular effects with more stable BP and heart rate profiles throughout the day. 2

• Short-acting stimulants create rapid peaks and troughs that can exacerbate BP elevation and cause rebound hypertension when they wear off. 2

Evidence on Stimulant-Related Blood Pressure Effects

• Stimulants cause modest increases in BP, with average elevations of 1–4 mmHg for both systolic and diastolic pressure across multiple studies. 2, 4, 5

• However, 5–15% of individuals may experience more substantial BP increases, requiring closer monitoring. 2, 6

• A 2023 long-term safety study (ADDUCE) found that methylphenidate-related pulse and BP changes, although relatively small, require regular monitoring but did not result in clinically significant adverse cardiovascular events over 2 years. 4

• A 2025 Cochrane review confirmed that daily amphetamines increase systolic BP by 1.93 mmHg and diastolic BP by 1.84 mmHg, with these effects sustained over time. 5

When to Consider Switching to Non-Stimulant ADHD Medications

• Atomoxetine is recommended as a first-choice non-stimulant option for patients with controlled hypertension due to its minimal impact on BP compared to stimulants. 2

• Alpha-2 adrenergic agonists (extended-release guanfacine or clonidine) are particularly beneficial because they may actually lower BP by 1–4 mmHg, opposite to stimulant effects. 2

• Switching should be considered only if the patient develops stage 2 hypertension (≥140/90 mmHg) that is clearly medication-induced despite optimal antihypertensive therapy. 2

Critical Pitfalls to Avoid

• Do not discontinue an effective stimulant solely based on BP at the 97th percentile without confirming true hypertension through repeat measurements. 1, 2

• Do not delay BP monitoring while continuing stimulant therapy; establish a regular monitoring schedule immediately. 2, 6

• Do not assume BP elevation is solely due to the stimulant; conduct a comprehensive evaluation for other secondary causes of hypertension in adolescents. 2

• Do not use short-acting stimulants as first-line treatment in patients with elevated BP, as they create cardiovascular instability. 2